Full Text Journal Articles by
Author Hoi Kei Lon


Find full text journal articles

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.

Günter U Höglinger, Irene Litvan, Nuno Mendonca, Deli Wang, Hui Zheng, Beatrice Rendenbach-Mueller, Hoi-Kei Lon, Ziyi Jin, Nahome Fisseha, Kumar Budur, Michael Gold, Davis Ryman, Hana Florian, ,

<h4>Background</h4>Progressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the safety and efficacy of tilavonemab for the treatment of progressive supranuclear palsy.<h4>Methods</h4>We did a phase 2, multicentre, randomised, placebo-controlled, double-blind study ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):182-192]

Cited: 0 times

View full text PDF listing >>

Pharmacokinetic Comparability of Risankizumab Formulations in Prefilled Syringe and Auto-injector for Subcutaneous Injection.

Hoi-Kei Lon, Ling Cheng, Sai Nudurupati, Ralf Loebbert, Rachel Duan, Jasmina Kalabic, Yinuo Pang,

<h4>Purpose</h4>Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that inhibits the p19 subunit of interleukin 23 from interacting with its receptor for the treatment of moderate to severe plaque psoriasis. The aim of this Phase I biopharmaceutics bridging study was to evaluate the pharmacokinetic comparability, immunogenicity, and tolerability of the ... Read more >>

Clin Ther (Clinical therapeutics)
[2021, :]

Cited: 0 times

View full text PDF listing >>


Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies.

Hoi-Kei Lon, Nuno Mendonca, Sandra Goss, Ahmed A Othman, Ahmed A Othman, Charles Locke, Ziyi Jin, Beatrice Rendenbach-Mueller,

Alicapistat is an orally active selective inhibitor of calpain 1 and 2 whose overactivation has been linked to Alzheimer disease (AD). Three studies were conducted in healthy subjects (18-55 years), 1 in healthy elderly subjects (≥65 years), and 1 in patients with mild to moderate AD. Four studies assessed pharmacokinetics, 1 study ... Read more >>

Clin Pharmacol Drug Dev (Clinical pharmacology in drug development)
[2019, 8(3):290-303]

Cited: 1 time

View full text PDF listing >>

Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images.

Shengwen Guo, Chunren Lai, Congling Wu, Guiyin Cen, ,

Neuroimaging measurements derived from magnetic resonance imaging provide important information required for detecting changes related to the progression of mild cognitive impairment (MCI). Cortical features and changes play a crucial role in revealing unique anatomical patterns of brain regions, and further differentiate MCI patients from normal states. Four cortical features, ... Read more >>

Front Aging Neurosci (Frontiers in aging neuroscience)
[2017, 9:146]

Cited: 5 times

View full text PDF listing >>

Oligonucleotide-Based Drug Development: Considerations for Clinical Pharmacology and Immunogenicity.

Jian Wang, Hoi-Kei Lon, Shwu-Luan Lee, Gilbert J Burckart, David S Pisetsky,

The field of oligonucleotide (OGN)-based therapeutics has been growing dramatically in the past decade, providing innovative platforms to develop agents for the treatment of a wide variety of clinical conditions. OGN agents have unique physicochemical properties and pharmacokinetic/pharmacodynamic characteristics. This review considers findings from the literature and information on new ... Read more >>

Ther Innov Regul Sci (Therapeutic innovation & regulatory science)
[2015, 49(6):861-868]

Cited: 1 time

View full text PDF listing >>

Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats.

Hoi-Kei Lon, Debra C DuBois, Justin C Earp, Richard R Almon, William J Jusko,

A mechanism-based model was developed to characterize the crosstalk between proinflammatory cytokines, bone remodeling biomarkers, and bone mineral density (BMD) in collagen-induced arthritic (CIA) rats. Male Lewis rats were divided into five groups: healthy control, CIA control, CIA receiving single 0.225 mg kg(-1) subcutaneous (SC) dexamethasone (DEX), CIA receiving single 2.25 mg kg(-1) SC ... Read more >>

Pharmacol Res Perspect (Pharmacology research & perspectives)
[2015, 3(5):e00169]

Cited: 1 time

View full text PDF listing >>

Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach.

Hoi-Kei Lon, Dongyang Liu, Debra C DuBois, Richard R Almon, William J Jusko,

The PK/PD of abatacept, a selective T cell co-stimulation modulator, was examined in rats with collagen-induced arthritis (CIA) using a nonlinear mixed effect modeling approach. Male Lewis rats underwent collagen induction to produce rheumatoid arthritis. Two single-dose groups received either 10 mg/kg intravenous (IV) or 20 mg/kg subcutaneous (SC) abatacept, ... Read more >>

J Pharmacokinet Pharmacodyn (Journal of pharmacokinetics and pharmacodynamics)
[2013, 40(6):701-712]

Cited: 7 times

View full text PDF listing >>

Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats.

Dong-Yang Liu, Hoi-Kei Lon, Yan-Lin Wang, Debra C DuBois, Richard R Almon, William J Jusko,

Methotrexate (MTX) is an anchor drug used to treat rheumatoid arthritis (RA), but responsiveness is variable in effectiveness and toxicity. Methotrexate and its polyglutamate conjugates (MTXPG(n)) in red blood cells (RBC) have been associated with patient response. In the current study, 13 collagen-induced arthritic (CIA) rats and 12 healthy rats ... Read more >>

Biopharm Drug Dispos (Biopharmaceutics & drug disposition)
[2013, 34(4):203-214]

Cited: 13 times

View full text PDF listing >>

Pharmacokinetic/pharmacodynamic modeling in inflammation.

Hoi-Kei Lon, Dongyang Liu, William J Jusko,

Inflammation is an array of immune responses to infection and injury. It results from a complex immune cascade and is the basis of many chronic diseases such as arthritis, diabetes, and cancer. Numerous mathematical models have been developed to describe the disease progression and effects of anti-inflammatory drugs. This review ... Read more >>

Crit Rev Biomed Eng (Critical reviews in biomedical engineering)
[2012, 40(4):295-312]

Cited: 12 times

View full text PDF listing >>

Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.

Dongyang Liu, Hoi-Kei Lon, Debra C Dubois, Richard R Almon, William J Jusko,

A population pharmacokinetic-pharmacodynamic-disease progression (PK/PD/DIS) model was developed to characterize the effects of anakinra in collagen-induced arthritic (CIA) rats and explore the role of interleukin-1β (IL-1β) in rheumatoid arthritis. The CIA rats received either vehicle, or anakinra at 100 mg/kg for about 33 h, 100 mg/kg for about 188 h, ... Read more >>

J Pharmacokinet Pharmacodyn (Journal of pharmacokinetics and pharmacodynamics)
[2011, 38(6):769-786]

Cited: 16 times

View full text PDF listing >>

Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis.

Hoi-Kei Lon, Dongyang Liu, Qi Zhang, Debra C DuBois, Richard R Almon, William J Jusko,

<h4>Purpose</h4>To develop a pharmacokinetic-pharmacodynamic disease progression (PK/PD/DIS) model to characterize the effect of etanercept in collagen-induced arthritis (CIA) rats on rheumatoid arthritis (RA) progression.<h4>Methods</h4>The CIA rats received either 5 mg/kg intravenous (IV), 1 mg/kg IV, or 5 mg/kg subcutaneous (SC) etanercept at day 21 post-disease induction. Effect on disease progression ... Read more >>

Pharm Res (Pharmaceutical research)
[2011, 28(7):1622-1630]

Cited: 22 times

View full text PDF listing >>

Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice.

Melanie A Felmlee, Hoi-Kei Lon, Frank J Gonzalez, Ai-Ming Yu,

Analysis of the developmental and sexual expression of cytochrome P450 drug-metabolizing enzymes is impeded by multiple and varied external factors that influence its regulation. In the present study, a CYP2D6/CYP3A4-double transgenic (Tg-CYP2D6/CYP3A4) mouse model was employed to investigate hepatic CYP2D6 and CYP3A4 ontogeny and sexual dimorphism. Both age and sex ... Read more >>

Drug Metab Dispos (Drug metabolism and disposition: the biological fate of chemicals)
[2008, 36(2):435-441]

Cited: 33 times

View full text PDF listing >>


1.656 s